| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net cash flows provided by (used in) financing activities | 5,940,285 | 3,094,438 | 3,094,438 |
| Net change in cash | 1,944,638 | 202,600 | 1,342,910 |
| Cash and cash equivalents at beginning of period | 3,633 | - | - |
| Cash and cash equivalents at end of period | 1,948,271 | - | - |
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)